Andrew B. Lassman '97 Appointed Vice Dean of Clinical Trials at VP&S
Andrew B. Lassman '97 has been appointed vice dean of clinical trials at the Vagelos College of Physicians and Surgeons (VP&S), a newly created role designed to accelerate and coordinate VP&S’s growing clinical trials enterprise. A professor of neurology, Dr. Lassman has internationally renowned expertise as a translational clinical trialist for brain tumors, focused on experimental therapeutics.
“With Dr. Lassman’s leadership, we aim to expand and optimize VP&S’s clinical trial footprint to position Columbia as a premier site globally for scientifically impactful and medically meaningful clinical trials,” said Katrina Armstrong, MD, dean of VP&S and executive vice president for health and biomedical sciences.
Dr. Lassman will continue in his current roles as vice chair for clinical research in the Department of Neurology, chief of the Division of Neuro-Oncology, and associate director for clinical trials at the NCI-designated Herbert Irving Comprehensive Cancer Center (HICCC). In his new role as vice dean, he will further develop and support VP&S’s infrastructure for this work, both at HICCC and across new areas, expanding the responsibilities of his former role as associate dean of clinical research compliance.
After earning his medical degree from VP&S, Dr. Lassman completed postgraduate training at Mount Sinai, NewYork-Presbyterian/Columbia University Irving Medical Center, and Memorial Sloan Kettering Cancer Center. He has served as principal investigator for more than 50 brain cancer studies including multicenter prospective trials conducted through the National Cancer Institute (NCI) sponsored National Clinical Trials Networks, with partnerships across both NCI and industry. He has authored more than 150 peer-reviewed publications, including 14 widely adopted clinical guidelines. He is recognized as a fellow of both the American Academy of Neurology (FAAN) and American Society of Clinical Oncology (FASCO), and has received clinical research awards from the Society for Neuro-Oncology and the European Association of Neuro-Oncology.